Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

NCT04754594

Last updated date
Study Location
Wits Reproductive Health and HIV Institute (Wits RHI) Shandukani Research Centre
Johannesburg, Gauteng, 2001, South Africa
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
SARS-CoV-2 Infection, COVID-19, Maternal Immunization
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications.

2. Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

3. Healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study

4. Documented negative HIV antibody test (Phase 2 only), syphilis test, and HBV surface antigen test during this pregnancy and prior to randomization

5. Participant is willing to give informed consent for her infant to participate in the study

6. Capable of giving signed informed consent

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Other medical or psychiatric condition including recent (within the past year) or
active suicidal ideation/behavior or laboratory abnormality that may increase the risk
of study participation or, in the investigator's judgment, make the participant
inappropriate for the study.


2. Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result
was not available) or microbiological (based on COVID-19 symptoms/signs and a positive
SARS-CoV-2 NAAT result) diagnosis of COVID 19.


3. History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the study intervention or any related
vaccine.


4. Participants with known or suspected immunodeficiency.


5. Bleeding diathesis or condition associated with prolonged bleeding that would in the
opinion of the investigator contraindicate intramuscular injection.


6. Previous vaccination with any coronavirus vaccine.


7. Receipt of medications intended to prevent COVID 19.


8. Receipt of blood/plasma products or immunoglobulin, from 60 days before administration
of study intervention, or planned receipt through delivery, with 1 exception, anti-D
immunoglobulin (eg, RhoGAM), which can be given at any time.


9. Current alcohol abuse or illicit drug use.


10. Participants who receive treatment with immunosuppressive therapy, including cytotoxic
agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or
planned receipt through the postvaccination blood draw.


11. Participation in other studies involving study intervention within 28 days prior to
study entry and/or during study participation.


12. Previous participation in other studies involving study intervention containing LNPs.


13. Investigator site staff or Pfizer employees directly involved in the conduct of the
study, site staff otherwise supervised by the investigator, and their respective
family members.


14. Participants whose unborn baby has been fathered by investigational site staff members
directly involved in the conduct of the study or their family members, site staff
members otherwise supervised by the investigator, or Pfizer employees directly
involved in the conduct of the study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

SARS-CoV-2 Infection, COVID-19, Maternal ImmunizationStudy to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
NCT04754594
  1. Johannesburg, Gauteng
  2. Soweto, Gauteng
  3. London, Greater London
  4. Birmingham, Alabama
  5. Birmingham, Alabama
  6. Birmingham, Alabama
  7. Mobile, Alabama
  8. Glendale, Arizona
  9. Goodyear, Arizona
  10. Phoenix, Arizona
  11. Phoenix, Arizona
  12. Huntington Park, California
  13. Huntington Park, California
  14. Lancaster, California
  15. Los Angeles, California
  16. Los Angeles, California
  17. Loxahatchee Groves, Florida
  18. Ammon, Idaho
  19. Blackfoot, Idaho
  20. Idaho Falls, Idaho
  21. Idaho Falls, Idaho
  22. Idaho Falls, Idaho
  23. Idaho Falls, Idaho
  24. Chicago, Illinois
  25. Chicago, Illinois
  26. Chicago, Illinois
  27. Chicago, Illinois
  28. Chicago, Illinois
  29. Saginaw, Michigan
  30. Saginaw, Michigan
  31. Anaconda, Montana
  32. Butte, Montana
  33. Butte, Montana
  34. Great Falls, Montana
  35. Great Falls, Montana
  36. Hamilton, Montana
  37. Helena, Montana
  38. Helena, Montana
  39. Missoula, Montana
  40. Missoula, Montana
  41. Missoula, Montana
  42. Missoula, Montana
  43. Missoula, Montana
  44. Ronan, Montana
  45. Hastings, Nebraska
  46. Norfolk, Nebraska
  47. Erie, Pennsylvania
  48. Erie, Pennsylvania
  49. Erie, Pennsylvania
  50. Erie, Pennsylvania
  51. West Reading, Pennsylvania
  52. West Reading, Pennsylvania
  53. West Reading, Pennsylvania
  54. West Reading, Pennsylvania
  55. West Reading, Pennsylvania
  56. Austin, Texas
  57. Austin, Texas
  58. Bedford, Texas
  59. Dallas, Texas
  60. Edinburg, Texas
  61. Fort Worth, Texas
  62. Fort Worth, Texas
  63. Fort Worth, Texas
  64. McAllen, Texas
  65. Plano, Texas
  66. Weatherford, Texas
  67. Weatherford, Texas
  68. Salt Lake City, Utah
  69. Salt Lake City, Utah
  70. Norfolk, Virginia
  71. Norfolk, Virginia
  72. Belo Horizonte, Minas Gerais
  73. Belo Horizonte, Minas Gerais
  74. Porto Alegre, RIO Grande DO SUL
  75. Sorocaba, SAO Paulo
  76. Sorocaba, SAO Paulo
  77. Sorocaba, SP
  78. São Bernardo do Campo, SÃO Paulo
  79. São Bernardo do Campo, SÃO Paulo
  80. Benoni, Gauteng
  81. Pretoria, Gauteng
  82. Cape Town, Western CAPE
  83. Cape Town, Western CAPE
  84. Santiago de Compostela, A Coruna
  85. Boadilla del Monte, Madrid
  86. Antequera, Malaga
  87. Barcelona,
  88. Barcelona,
  89. Mostoles,
  90. Sevilla,
  91. Sevilla,
  92. Southampton, Hampshire
  93. Southampton, Hampshire
  94. Gillingham, Kent
  95. Manchester, Lancashire
  96. Edinburgh, Midlothian
  97. Edinburgh, Scotland
  98. Leeds,
  99. London,
  100. London,
  101. London,
  102. London,
  103. London,
  104. Newcastle upon Tyne,
  105. Oxford,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
Official Title  ICMJE A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER
Brief Summary This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability, and immunogenicity of 30 µg of BNT162b2 or placebo administered in 2 doses, 21 days apart, in approximately 700 healthy pregnant women 18 years of age or older vaccinated at 24 to 34 weeks' gestation. Participants will be randomized 1:1 to receive BNT162b2 or placebo (saline).
Detailed Description

The Phase 2 portion of the study will include approximately 200 pregnant women randomized 1:1 to receive BNT162b2 or placebo (saline) at 27 to 34 weeks' gestation. IRC review of safety data through 7 days after the second dose for all Phase 2 participants will be completed.

The Phase 3 portion of this study will assess the safety, tolerability, and immunogenicity of BNT162b2 among pregnant women enrolled at 24 to 34 weeks' gestation.

Maternal participants who originally received placebo will receive BNT162b2 at defined time points as part of the study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Condition  ICMJE
  • SARS-CoV-2 Infection
  • COVID-19
  • Maternal Immunization
Intervention  ICMJE
  • Biological: BNT162b2
    Intramuscular Injection
  • Other: Placebo
    Intramuscular Injection
Study Arms  ICMJE
  • Experimental: BNT162b2
    2 doses
    Intervention: Biological: BNT162b2
  • Placebo Comparator: Placebo
    2 doses
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 27, 2021)
700
Original Estimated Enrollment  ICMJE
 (submitted: February 11, 2021)
4000
Estimated Study Completion Date  ICMJE June 23, 2022
Estimated Primary Completion Date June 23, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Healthy women ?18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications.
  2. Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  3. Healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study
  4. Documented negative HIV antibody test (Phase 2 only), syphilis test, and HBV surface antigen test during this pregnancy and prior to randomization
  5. Participant is willing to give informed consent for her infant to participate in the study
  6. Capable of giving signed informed consent

Exclusion Criteria:

  1. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  2. Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.
  3. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine.
  4. Participants with known or suspected immunodeficiency.
  5. Bleeding diathesis or condition associated with prolonged bleeding that would in the opinion of the investigator contraindicate intramuscular injection.
  6. Previous vaccination with any coronavirus vaccine.
  7. Receipt of medications intended to prevent COVID 19.
  8. Receipt of blood/plasma products or immunoglobulin, from 60 days before administration of study intervention, or planned receipt through delivery, with 1 exception, anti-D immunoglobulin (eg, RhoGAM), which can be given at any time.
  9. Current alcohol abuse or illicit drug use.
  10. Participants who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt through the postvaccination blood draw.
  11. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
  12. Previous participation in other studies involving study intervention containing LNPs.
  13. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  14. Participants whose unborn baby has been fathered by investigational site staff members directly involved in the conduct of the study or their family members, site staff members otherwise supervised by the investigator, or Pfizer employees directly involved in the conduct of the study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Brazil,   South Africa,   Spain,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04754594
Other Study ID Numbers  ICMJE C4591015
2020-005444-35 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party BioNTech SE
Study Sponsor  ICMJE BioNTech SE
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account BioNTech SE
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP